First Trust Direct Indexing’s Supernus Pharmaceuticals SUPN Stock Holding History

First Trust Direct Indexing’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,209	Closed	-$312K	–	704
2022 Q3	$312K	Sell	9,209 -464	-5%	-$15.1K	0.05%	460
2022 Q2	$280K	Buy	9,673 +770	+9%	+$22.1K	0.04%	490
2022 Q1	$288K	Buy	8,903 +720	+9%	+$22.1K	0.04%	521
2021 Q4	$239K	Hold	8,183	–	–	0.03%	556
2021 Q3	$218K	Buy	+8,183	New	+$220K	0.03%	570
2021 Q1	–	Sell	-6,782	Closed	-$171K	–	921
2020 Q4	$171K	Buy	+6,782	New	+$146K	0.05%	377

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

First Trust Direct Indexing's SUPN Position: Q4 2022 in Review

First Trust Direct Indexing sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 9,209 shares — an estimated $312K sold.

First Trust Direct Indexing first reported a position in SUPN in Q4 2020 and held it in 6 quarters. The position peaked at $312K in Q3 2022. 263 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

First Trust Direct Indexing reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
First Trust Direct Indexing sold 9,209 Supernus Pharmaceuticals shares in Q4 2022, an estimated $312K.
First Trust Direct Indexing first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 6 quarters.
First Trust Direct Indexing's Supernus Pharmaceuticals position peaked at $312K in Q3 2022.
263 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on First Trust Direct Indexing's 13F filing for Q4 2022, filed 20 Jan 2023.